Senior Study Scientist Rhiannon holds a Masters degree in Immunology from the University of Strathclyde. Since 2016, she has built extensive experience within both GxP-regulated and non-regulated CRO environments, focusing on the biological characterisation and effector function analysis of antibody-based biosimilars. She joined Roukenbio in 2020 and has particular interest in qualification and validation of bioassays, potency assay development, and multiplex cytokine release assays.
Resources
Research Posters
30 June 2026
|4 min read
This poster illustrates how complex primary cell-based assays contribute to biosimilar comparability by addressing key mechanisms of action and fulfilling roles central to regulatory expectations integrating biological activity assessment, indication extrapolation and the linkage of analytical data with clinical relevance.
Research Posters
15 May 2026
|5 min read
Proving biosimilar comparability requires more than assumed Fc silencing. Even widely used ‘silent’ mutations can retain residual activity, making advanced binding and functional assays essential to accurately characterise Fc properties and meet regulatory expectations.
Research Posters
7 May 2024
|3 min read
Effective IgG1 Fc silencing: characterisation of residual binding and functional activity. See data in our research poster.
